Needham & Company
-
Stocks Showing 'Golden Cross' Pattern 06/21: (ABX) (ENDP) (FNSR) (CYTK)
-
Notable Analyst Rating Changes 04/11: (LMT) (LRCX) (ADBE) Upgraded; (MSFT) (FTNT) (BRCM) Downgraded
-
Ugly Stick Set to Tee-off on Endo Health (ENDP) Stock
-
Notable Analyst Rating Changes 12/14: (HST) (MRO) (WBMD) Upgraded; (CME) (XOM) (CLWR) Downgraded
-
Needham & Company Downgrades Endo Pharmaceuticals Holdings Inc (ENDP) to Underperform
-
Needham & Company Maintains a 'Hold' on Par Pharmaceutical (PRX); Is Endo (ENDP) the 'Mystery Bidder'
-
Needham & Company on Endo Pharmaceuticals (ENDP): Watson (WPI) Gains First Generic Lidoderm Approval; A Few Other Issues Too
-
Needham & Company Maintains a 'Hold' on Watson Pharmaceuticals (WPI); Lidoderm Settlement A Mild Plus
-
Needham & Company Maintains a 'Strong Buy' on Mylan (MYL)l Mid-May Is D-Day for Generic Lidoderm, Not July
-
Needham & Company Maintains a 'Hold' on Endo Pharmaceuticals (ENDP); Solid 3Q11 Results Highlight Strength in Branded and Generic Pharma Business
-
Needham & Company Maintains a 'Hold' on Endo Pharmaceuticals (ENDP); Qualitest & Strong Opana ER Trends Trigger Another Round Of Boosted Projections
-
Daily State of the Markets 09/29: A Complete Contradiction?
-
Notable Analyst Rating Changes 07/19: KG, ATHR, SSYS, YHOO Upgraded; ADCT, ENDP, MFC, PRGO Downgraded
-
Notable Analyst Ratings Changes 12/08: UAUA, CBS, STP, JASO, AGU, SYY Upgraded; S, ENDP, CCJ, BEAV Downgraded